{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:41:45Z","timestamp":1777509705888,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck Frosst-Schering Pharmaceuticals","award":["35910"],"award-info":[{"award-number":["35910"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.atherosclerosis.2015.12.032","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T17:50:42Z","timestamp":1450979442000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe"],"prefix":"10.1016","volume":"246","author":[{"given":"Morris","family":"Schweitzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miltiadis","family":"Paliouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenore K.","family":"Beitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Trifiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafinaz F.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naif M.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine E.","family":"Chalifour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists, C","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0022-2275(20)35728-X","article-title":"Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans","volume":"34","author":"Dietschy","year":"1993","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.14.99","article-title":"Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia","volume":"14","author":"Davis","year":"2007","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib5","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib6","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3748\/wjg.v12.i40.6429","article-title":"Emerging roles of the intestine in control of cholesterol metabolism","volume":"12","author":"Kruit","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/geno.2000.6151","article-title":"Evidence for a Niemann\u2013Pick C (NPC) gene family: identification and characterization of NPC1L1","volume":"65","author":"Davies","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib9","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/mol.106.027896","article-title":"In\u00a0vivo responsiveness to ezetimibe correlates with Niemann-Pick C1 Like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs","volume":"71","author":"Hawes","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib11","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1194\/jlr.M027359","article-title":"Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine","volume":"53","author":"Chang","year":"2012","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib12","doi-asserted-by":"crossref","first-page":"11140","DOI":"10.1073\/pnas.0800936105","article-title":"Extracellular loop C of NPC1L1 is important for binding to ezetimibe","volume":"105","author":"Weinglass","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrc3723","article-title":"Mining the genomes of exceptional responders","volume":"14","author":"Chang","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.numecd.2009.03.023","article-title":"An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia","volume":"20","author":"Mart\u00edn","year":"2010","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/hmg\/ddn108","article-title":"Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes","volume":"17","author":"Fahmi","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-4-16","article-title":"NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe","volume":"4","author":"Hegele","year":"2005","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib17","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1073\/pnas.0508483103","article-title":"Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels","volume":"103","author":"Cohen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/FPC.0b013e3283327925","article-title":"In-vitro characterization of the six clustered variants of NPC1L1 observed in cholesterol low absorbers","volume":"19","author":"Yamanashi","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1194\/jlr.P001172","article-title":"Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly","volume":"51","author":"Polisecki","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5551\/jat.2451","article-title":"A\u00a0SNP of NPC1L1 affects cholesterol absorption in Japanese","volume":"17","author":"Maeda","year":"2010","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ygeno.2005.08.007","article-title":"Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment","volume":"86","author":"Simon","year":"2005","journal-title":"Genomics"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib22","doi-asserted-by":"crossref","first-page":"e18722","DOI":"10.1371\/journal.pone.0018722","article-title":"The structure of the NPC1L1 N-terminal domain in a closed conformation","volume":"6","author":"Kwon","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cell.2009.03.049","article-title":"Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol","volume":"137","author":"Kwon","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib24","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple Amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib28","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5 log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J.\u00a0Comput. Phys."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/ci600406v","article-title":"Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space","volume":"47","author":"Na\u00efm","year":"2007","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib31","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1021\/pr801106a","article-title":"Enhanced sensitivity in proteomics experiments using FAIMS coupled with a hybrid linear ion trap\/Orbitrap mass spectrometer","volume":"8","author":"Saba","year":"2009","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1142\/S021972000300023X","article-title":"Bioinformatics meets proteomics\u2013bridging the gap between mass spectrometry data analysis and cell biology","volume":"1","author":"Kearney","year":"2003","journal-title":"J.\u00a0Bioinform. Comput. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.0009-9163.2004.00223.x","article-title":"The \u0394>15\u00a0Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec","volume":"65","author":"Simard","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.1014434108","article-title":"Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake","volume":"108","author":"Ge","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib35","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Stitziel","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib36","series-title":"IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)","author":"Cannon","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib37","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1056\/NEJMc1500124","article-title":"Mutations in NPC1L1 and coronary heart disease","volume":"372","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.atherosclerosis.2015.07.011","article-title":"Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients","volume":"242","author":"Muendlein","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0004.2004.00388.x","article-title":"Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe","volume":"67","author":"Wang","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib41","doi-asserted-by":"crossref","first-page":"25088","DOI":"10.1074\/jbc.M111.244475","article-title":"The N-terminal domain of NPC1L1 protein binds cholesterol and plays essential roles in cholesterol uptake","volume":"286","author":"Zhang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nn.2781","article-title":"Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT","volume":"14","author":"Cremona","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib44","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1016\/j.febslet.2006.08.077","article-title":"A\u00a0new paradigm for membrane-organizing and -shaping scaffolds","volume":"580","author":"Bauer","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib45","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1242\/jcs.092015","article-title":"The roles of flotillin microdomains \u2013 endocytosis and beyond","volume":"124","author":"Otto","year":"2011","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.12.032_bib47","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015302616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015302616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T18:43:06Z","timestamp":1653936186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015302616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":47,"alternative-id":["S0021915015302616"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.12.032","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}